UK markets closed

Equillium, Inc. (0A4D.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.7700-0.1315 (-6.92%)
At close: 04:53PM BST
Full screen
Previous close1.9015
Open1.7768
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.7700 - 1.7768
52-week range0.4900 - 3.1200
Volume145
Avg. volume2,796
Market capN/A
Beta (5Y monthly)1.67
PE ratio (TTM)N/A
EPS (TTM)-2.2540
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    LA JOLLA, Calif., April 03, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee appr

  • Zacks

    5 Stocks That More Than Doubled in Q1 With More Gains Ahead

    Equillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.

  • Business Wire

    Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

    LA JOLLA, Calif., April 01, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients. The data suggests high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added t